Skip to main content

Table 4 Best Objective Response by irRC and RECIST v1.1

From: Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

n (%) irRC RECIST
Immunotherapy-Naive (n = 39) Prior Immunotherapy (n = 11) Immunotherapy-Naive (n = 39) Prior Immunotherapy (n = 11)
Objective response rate 10 (25.6) 0 9 (23.1) 0
 Complete response 3 (7.7) 0 3 (7.7) 0
 Partial response 7 (17.9) 0 6 (15.4) 0
Stable disease 15 (38.5) 4 (36.4) 10 (25.6) 3 (27.3)
Disease control rate 25 (64.1) 4 (36.4) 19 (48.7) 3 (27.3)
Progressive disease 7 (17.9) 5 (45.5) 15 (38.5) 6 (54.5)
Missing 7 (17.9) 2 (18.2) 5 (12.8) 2 (18.2)
  1. irRC immune-related response criteria, RECIST Response Evaluation Criteria in Solid Tumors